Sun Pharma and Cipla seen as having more upside
Systematix analyst Vishal Manchanda said Sun Pharmaceutical Industries and Cipla offer relatively better upside among large-cap pharma stocks. He added that increasing licensing deals with Chinese drugmakers could help lower oncology drug prices in India.
Sun Pharmaceutical Industries and Cipla offer relatively better upside among large-cap pharma stocks, while increasing licensing deals with Chinese drugmakers could help bring down oncology drug prices in India, according to Vishal Manchanda, Pharma Analyst at Systematix Group.Manchanda believes mo…